CN¥284.30
1.75% today
Shanghai, Nov 19, 02:44 am CET
ISIN
CH1391448177
Symbol
688235

BeOne Medicines Stock price

CN¥289.37
+14.82 5.40% 1M
+57.38 24.73% 6M
+128.35 79.71% YTD
+133.16 85.24% 1Y
+161.28 125.91% 3Y
+128.39 79.76% 5Y
+128.39 79.76% 10Y
+128.39 79.76% 20Y
Shanghai, Closing price Tue, Nov 18 2025
-1.41 0.48%
ISIN
CH1391448177
Symbol
688235
Industry

Key metrics

Basic
Market capitalization
CN¥296.2b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 279.6
P/S
8.3 | 7.9
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
56.4%
Return on Equity
-20.6%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
CN¥35.7b | CN¥37.6b
EBITDA
- | CN¥2.9b
EBIT
CN¥1.0b | CN¥1.5b
Net Income
CN¥-153.0m | -
Free Cash Flow
CN¥3.3b
Growth (TTM | estimate)
Revenue
50.6% | 38.3%
EBITDA
- | 179.3%
EBIT
115.7% | 134.2%
Net Income
97.7% | -
Free Cash Flow
140.5%
Margin (TTM | estimate)
Gross
86.0%
EBITDA
- | 7.7%
EBIT
2.9%
Net
-0.4% | -
Free Cash Flow
9.3%
More
EPS
CN¥-0.1
FCF per Share
-
Short interest
-
Employees
11k
Rev per Employee
CN¥2.5m
Show more

Is BeOne Medicines a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

BeOne Medicines Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a BeOne Medicines forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a BeOne Medicines forecast:

Buy
93%
Hold
7%

Financial data from BeOne Medicines

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
35,673 35,673
51% 51%
100%
- Direct Costs 4,997 4,997
25% 25%
14%
30,676 30,676
56% 56%
86%
- Selling and Administrative Expenses 14,685 14,685
18% 18%
41%
- Research and Development Expense 15,133 15,133
10% 10%
42%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,020 1,020
116% 116%
3%
Net Profit -153 -153
98% 98%
0%

In millions CNY.

Don't miss a Thing! We will send you all news about BeOne Medicines directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Head office Cayman Islands
Employees 11,000
Website

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today